期刊文献+

唑来膦酸治疗绝经后骨质疏松早期药物不良反应分析 被引量:19

Early side effects of zoledronic acid in treating postmenopausal osteoporosis
原文传递
导出
摘要 目的:为了解唑来膦酸注射液治疗绝经后骨质疏松后早期不良反应情况及发生率,分析骨密度、合并骨折、应用钙剂、骨吸收抑制剂与早期不良反应的相关性。方法:对2009年-2010年12月期间行5mg唑来膦酸注射液治疗绝经后骨质疏松58例患者进行随访,记录用药后30 d内不良反应及其发生率,并进行分析。结果:唑来膦酸用药后早期不良反应主要表现为发热、肌肉痛、流感样症状、头痛、关节痛等症状,其发生率分别为48.3%,25.9%,31.0%,41.4%,24.2%。总不良反应率为60.3%。多为一过性,用药后30 d内均完全缓解。经比较发现骨密度差异、是否合并骨折与不良反应发生率无明显统计学差异;治疗前是否应用钙剂在头痛、肌肉痛、关节痛的发生率反面有明显统计学差异(P<0.05)。治疗前是否应用骨吸收抑制剂药物史的患者与治疗后头痛、肌肉痛、关节痛的发生率有明显统计学差异(P<0.05)。结论:5 mg唑来膦酸注射液治疗早期安全性较高,不良反应症状多为一过性,早期不良反应发生率与骨密度、合并骨折无关,可能与钙剂、骨吸收抑制剂有关。用药前后应及时预防治疗,早期观察无严重后遗症。 Objective:To analyze early side effects of zoledronic acid in treating postmenopausal osteoporosis.Methods: Totally 58 postmenopausal osteoporosis patients treated with 5 mg zoledronic acid injection were followed-up between Mar 2009 and Dec 2010.The bone mineral density(BMD),osteoporosis fracture,application of calcium preparations and bone resorption inhibitors,and rate of early side effects within 30 days were analyzed.Results: The early side effects of zoledronic acid included fever(48.3%),muscle pain(25.9%),influenza-like symptoms(31.0%),headache(41.4%),and joint pain(24.2%).Total rate of side effects was 60.3%.They were transient,and vanished within 30 days after injection.BMD and osteoporosis fracture were irrelevant to the rates of side effects.However,application of calcium preparations and bone resorption inhibitors before injection was relevant to rates of headache,muscle pain and joint pain(P0.05).Conclusion: Zoledronic acid injection(5 mg) was relatively safe in early phase after injection.Most side effects are transient;the rates of side effects are irrelevant to BMD and osteoporosis fracture,but relevant to application of calcium preparations and bone resorption inhibitor before injection.
机构地区 北京医院骨科
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第8期757-760,共4页 Chinese Journal of New Drugs
关键词 唑来膦酸注射液 绝经后骨质疏松 不良反应发生率 钙剂 骨吸收抑制剂 zoledronic acid injection postmenopausal osteoporosis rate of adverse reaction calcium bone resorption inhibitor
  • 相关文献

参考文献8

  • 1孙瑞台.骨质疏松症的运动疗法应用及研究进展[J].国外医学(物理医学与康复学分册),1994,14(4):149-151. 被引量:11
  • 2DENNISON E, COOPER C. Epidemiology of osteoporotic fractures[ J]. Horm Res ,2000,54 (Suppl) 1:58 - 63.
  • 3COMPSTON JE,SEEMAN E. Compliance with osteoporosis therapy is the weakest link[ J]. Lancet,2006,368(9540) :973 -974.
  • 4SIRIS ES, HARRIS ST, ROSEN CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women : relationship to vertebral and nonvertebral fractures from 2 US claims databases[J]. Mayo Clin Proc,2006, 81 (8) :1013 - 1022.
  • 5BLACK DM,DELMAS PD,EASTELL R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[ J]. N Engl Med,2007,356(18) :1809 - 1822.
  • 6LYLES KW, COLON-EMERIC CS, MAGAZINER JS,et al. Zoledronic acid and clinical fractures and mortality after hip fracture [J].N Engl J Med, 2007,357(18) :1799 - 1809.
  • 7DUNFORD JE, THOMPSON K, COXON FP,et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates [ J ]. J Pharmacol Exp Ther, 2001,296 ( 2 ) : 235 - 242.
  • 8GREEN JR, MOLLER K, JAEGGI KA,et al. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound [ J ]. J Bone Miner Res, 1994,9 ( 5 ) :745 - 751.

共引文献10

同被引文献146

引证文献19

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部